Specific Targeting of Human Integrin α v β 3 with 111 In-Labeled Abegrin™ in Nude Mouse Models

Zhaofei Liu,Bing Jia,Huiyun Zhao,Xiaoyuan Chen,Fan Wang

DOI: https://doi.org/10.1007/s11307-010-0302-4

2010-01-01

Molecular Imaging and Biology

Abstract:Purpose The cell adhesion molecule integrin α v β 3 is an important player in the process of tumor angiogenesis and metastasis. Abegrin™, a fully humanized anti-integrin α v β 3 monoclonal antibody, was currently in clinical trials for cancer therapy. Herein, we labeled Abegrin™ with 111 In, evaluated the in vitro and in vivo characteristics, and investigated whether the expression of integrin α v β 3 in tumors could be imaged with 111 In-labeled Abegrin™. Methods The binding affinity and specificity of Abegrin™ was analyzed using U87MG glioblastoma cells. Abegrin™ was coupled with 1,4,7,10-tetraazadodecane- N , N ′, N ″, N ′″-tetraacetic acid (DOTA) for 111 In radiolabeling. γ Imaging of 111 In-DOTA–Abegrin™ was carried out in nude mice bearing both integrin α v β 3 -positive U87MG and integrin α v β 3 -negative HT-29 tumors. Biodistribution and blocking studies of 111 In-DOTA–Abegrin™ were investigated in U87MG tumor-bearing nude mice. Results Abegrin™ exhibited high-binding affinity to human integrin α v β 3 expressed on U87MG cells ( K d of 0.35 ± 0.06 nM). The antibody retained antigen-binding affinity/specificity after DOTA conjugation. γ Imaging showed that the tumor uptake of 111 In-DOTA–Abegrin™ in integrin α v β 3 -positive U87MG tumors was much higher than that in integrin α v β 3 -negative HT-29 tumors. In the HT-29 tumors, Abegrin™ was mainly nonspecifically accumulated around the blood vessels, while in the U87MG tumors, besides the nonspecific tumor retention, Abegrin™ also specifically bound the human integrin α v β 3 expressed on the tumor cells. Biodistribution and blocking studies exhibited that the U87MG tumor uptake of 111 In-DOTA–Abegrin™ decreased from 14.12 ± 0.44 to 6.93 ± 0.94 percentage of injected dose per gram of tissue after coinjection of excess dose of cold Abegrin™, which confirmed the in vivo integrin α v β 3 binding specificity of 111 In-DOTA–Abegrin™. Conclusions Abegrin™ showed specific binding to human integrin α v β 3 expressed on the tumor cells. 111 In-DOTA–Abegrin™ can specifically target the human integrin α v β 3 expression in the nude mouse model. 111 In-DOTA–Abegrin™ has a potential for clinical translation as an agent for integrin α v β 3 -positive tumor imaging, evaluating tumor angiogenic status and monitoring the therapeutic efficacy of Abegrin™-based cancer therapy.